Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.77 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.77 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211210 | 0.90 | SLC6A9 (0.78) | SLC6A9SLC6A5GPR139 | |
| SCHEMBL2007259 | 0.87 | SLC6A9 (1.00) | SLC6A9SLC6A5GPR139 | |
| SCHEMBL2006707 | 0.85 | SLC6A9 (0.85) | SLC6A9SLC6A5GPR139 | |
| SCHEMBL2011776 | 0.84 | SLC6A9 (0.93) | SLC6A9SLC6A5GPR139 | |
| SCHEMBL2014172 | 0.83 | SLC6A9 (0.83) | SLC6A9SLC6A5GPR139ALDH1A1 | |
| SCHEMBL2006465 | 0.81 | SLC6A9 (0.80) | SLC6A9SLC6A5GPR139 | |
| SCHEMBL2014824 | 0.81 | SLC6A9 (0.63) | SLC6A9SLC6A5GPR139ALDH1A1 | |
| SCHEMBL2014003 | 0.80 | SLC6A9 (0.80) | SLC6A9SLC6A5GPR139ALDH1A1SMN1; SMN2 | |
| SCHEMBL2007780 | 0.80 | SLC6A9 (0.59) | SLC6A9SLC6A5GPR139ALDH1A1SMN1; SMN2 | |
| SCHEMBL2013065 | 0.79 | SLC6A9 (0.88) | SLC6A9SLC6A5GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964645-B2 | Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | claimed |
| EP-2066620-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | claimed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | claimed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | claimed |
| US-7964645-B2 | Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964645-B2 | Glycine transporter gene 1 (GlyT-1); psychosis, schizophrenia, dementia; activation of NMDA receptors via GlyT-1 inhibition; N-(([(4-chloro-phenyl)-phenyl-methyl]-carbamoyl)-methyl)-4-fluorobenzamide for example | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2066620-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2008022938-A1 | DI-AROMATIC SUBSTITUTED AMIDES AS INHIBITORS FOR GLYT1 | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076806-A1 | Di-aromatic substituted amides as inhibitors for GlyT-1 | AGXT, SLC1A2, GRIA1 | SLC6A9 43/4885SLC6A5 30/4885GPR139 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.